03:30 PM EST - Forbes Medi-Tech Inc. : lost more than half their value on Monday after results from the U.S. Phase II trial of the cholesterol lowering drug, FM-VP4, failed to achieve the company's goals. The results missed the company's target of an average 15 percent reduction in LDL, or bad cholesterol. Forbes Medi-Tech Inc.
shares T.FMI are trading down $1.49 at $1.20.
